PSMA (prostate-specific membrane antigen), also known as FOLH1 (folate hydrolase 1), NAALAD1 (N-acetylated-α-linked acidic dipeptidase I), GCPII (glutamate  carboxypeptidase II), FGCP (folypoly¬γ¬glutamate carboxypeptidase ), and GIG27 (cell growth-inhibiting gene 27 protein), is a tumor marker in prostate cancer.  PSMA is a single pass type II transmembrane zinc metallopeptidase that belongs to the peptidase M28 family and M28B subfamily. PSMA is most highly expressed in the nervous system, prostate, kidney, and small intestine. PSMA has folate hydrolase and N-acetylated-α-linked-acidic dipeptidase (NAALADase) activity with a preference for tri-alpha-glutamate peptides. In the intestine, PSMA hydrolyzes folylpoly¬γ-glutamates, facilitating the uptake of folate. Genetic variation in PSMA may be associated with low folate levels and consequent hyperhomocysteinemia. In the brain, PSMA modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate, another neurotransmitter. Inhibition of brain PSMA activity is considered to be a promising approach for the treatment of neurological disorders associated with glutamate excitotoxicity, such as stroke, chronic pain, and amyotrophic lateral sclerosis. PSMA also exhibits a dipeptidyl-peptidase IV (DPPIV) type activity. PSMA is involved in tumor progression In the prostate and used as an effective diagnostic and prognostic indicator of prostate cancer.

PSMA (prostate-specific membrane antigen), also known as FOLH1 (folate hydrolase 1), NAALAD1 (N-acetylated-α-linked acidic dipeptidase I), GCPII (glutamate  carboxypeptidase II), FGCP (folypoly¬γ¬glutamate carboxypeptidase ), and GIG27 (cell growth-inhibiting gene 27 protein), is a tumor marker in prostate cancer.  PSMA is a single pass type II transmembrane zinc metallopeptidase that belongs to the peptidase M28 family and M28B subfamily. PSMA is most highly expressed in the nervous system, prostate, kidney, and small intestine. PSMA has folate hydrolase and N-acetylated-α-linked-acidic dipeptidase (NAALADase) activity with a preference for tri-alpha-glutamate peptides. In the intestine, PSMA hydrolyzes folylpoly¬γ-glutamates, facilitating the uptake of folate. Genetic variation in PSMA may be associated with low folate levels and consequent hyperhomocysteinemia. In the brain, PSMA modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate, another neurotransmitter. Inhibition of brain PSMA activity is considered to be a promising approach for the treatment of neurological disorders associated with glutamate excitotoxicity, such as stroke, chronic pain, and amyotrophic lateral sclerosis. PSMA also exhibits a dipeptidyl-peptidase IV (DPPIV) type activity. PSMA is involved in tumor progression In the prostate and used as an effective diagnostic and prognostic indicator of prostate cancer.

 

Product Details

 

Gene Symbol: PSMA; FOLH1; PSM; FGCP; FOLH; GCP2; mGCP; GCPII; NAALAD1; NAALAdase; CD3E; T3E; TCRE; IMD18; Leu-4

 

NCBI Gene ID: 2346; 916 

 

Uniprot Entry: Q04609; P07766

  

Construct Details: Expressed as a single-chain Fv (scFv) from anti-PSMA VH and VL region fused with a scFv of anti-CD3e VH and VL region with a His-tag at the C-terminus. Exists as a monomer under non-reducing and reducing condition.

 

Source: Mammalian cells stably expressing anti-PSMA:anti-CD3e bispecific antibody (in a scFv-scFv’ format) and growing in chemical-defined media with no animal component or antibiotics.

 

M.W.: Calculated molecular mass (kDa): 57.0. Estimated by SDS-PAGE under non-reducing condition(kDa): 55-60. Calculated extinction coefficients (M-1 cm-1, at 280nm):  121295.

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as DTT "+")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (concentration determined by UV spectrometry and verified by SDS-PAGE and Coomassie blue staining).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Recognizes PSMA on tumor cells and CD3e in the context of TCR complex on T cells.  Potently promotes T cell-mediated anti-tumor activity in vitro and in vivo after engaging with tumor cell surface antigen PSMA.

 

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Cancer Res. 53:227-230(1993)

2. Pro. Natl. Acad. Sci. 93:749 (1996)

3. Clin. Cancer Res. 3:81 (1997) 

4. J. Biol. Chem. 274:8470-8483(1999)

5. Prostate 67:1791-1800(2007)

 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL2617-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.